Novel membrane-targeted antibiotics against drug-resistant Gram-positive bacterial infections

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1113719

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This project aims to develop a best in class antibiotic, Vancapticin, with superior efficacy, broader spectra of action and improved therapeutic index than existing therapies for Gram-positive (G+ve) bacterial infections. The research team has identified lead candidates that offer equivalent &/or superior potency, efficacy & pharmacokinetic profiles compared to several clinical comparators. NHMRC Development funding is required to select a candidate for an Investigative New Drug application.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Development Grants

Funding Amount: $1,351,496.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medicinal and Biomolecular Chemistry not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Staphylococcus aureus | antibiotic resistance | drug discovery | drug resistance | pharmacokinetics

Related Links